Sunesis Pharmaceuticals Inc (SNSS):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Sunesis Pharmaceuticals Inc (SNSS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9927
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:58
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Sunesis Pharmaceuticals Inc (Sunesis), formerly Mosaic Pharmaceuticals, Inc. develops and markets cancer therapeutics for the treatment of solid and hematologic cancers. The company’s Vosaroxin is being developed in Phase III clinical trials for the treatment of acute myeloid leukemia (AML). It is a first-in-class anti-cancer quinolone derivative that has not been used previously for the treatment of cancer. The drug candidate is also being evaluated in Phase III clinical trials for the treatment of myelodysplastic syndromes (MDS). Its other products under pipeline include TAK-580 and SNS-510 for solid tumors, and Vecabrutinib (SNS-062) for B-cell malignancies. The company collaborates with pharmaceutical companies such as Biogen, Millennium Pharmaceuticals, Inc. and Sumitomo Dainippon to obtain licenses to develop certain products. Sunesis is headquartered in South San Francisco, California, the US.

Sunesis Pharmaceuticals Inc (SNSS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Sunesis Pharma Enters Into Licensing Agreement With Biogen Idec 11
Sunesis Pharma Enters Into Licensing Agreement With Millennium Pharma 13
Equity Offering 14
Sunesis Pharma to Raise up to USD15.5 Million in Private Placement of Shares 14
Sunesis Pharmaceuticals Raises USD20 Million in Public Offering of Shares 16
Sunesis Pharma Raises USD28 Million in Public Offering of Shares 18
Sunesis Pharma Raises USD17 Million in Public offering of Preferred Shares 20
Sunesis Pharma Raises USD9 Million in Public Offering of Shares 21
Sunesis Pharma Raises USD17 Million in Public Offering of Shares 23
Sunesis Pharma Prices Public offering of Shares for USD8 Million 25
Sunesis Pharma Completes Public Offering Of Common Stock And Warrants For US$43 Million 26
Asset Transactions 27
Royalty Pharma Completes Acquisition Of Royalty Agreement For Vosaroxin From Sunesis Pharma For US$25 Million 27
Sunesis Pharmaceuticals Inc – Key Competitors 29
Sunesis Pharmaceuticals Inc – Key Employees 30
Sunesis Pharmaceuticals Inc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Financial Announcements 32
Nov 05, 2018: Sunesis Pharmaceuticals reports third quarter 2018 financial results and recent highlights 32
Aug 07, 2018: Sunesis Pharmaceuticals reports second quarter 2018 financial results and recent highlights 33
May 08, 2018: Sunesis Pharmaceuticals Announces First Quarter 2018 Financial Results 35
Mar 08, 2018: Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Highlights 36
Nov 02, 2017: Sunesis Pharmaceuticals Reports Third Quarter 2017 Financial Results and Recent Highlights 38
Jul 27, 2017: Sunesis Pharmaceuticals Reports Second Quarter 2017 Financial Results and Recent Highlights 40
May 08, 2017: Sunesis Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Highlights 42
Mar 09, 2017: Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial Results and Recent Highlights 44
Corporate Communications 46
Jul 09, 2018: Sunesis Pharmaceuticals Announces Senior Management Changes 46
Feb 07, 2018: Sunesis Pharmaceuticals Appoints Industry Veteran H. Ward Wolff to the Board of Directors 47
Dec 04, 2017: Sunesis Pharmaceuticals Announces Change in Leadership 48
Nov 30, 2017: Sunesis Pharmaceuticals Appoints William Quinn as CFO and Senior Vice President, Finance and Corporate Development 49
Legal and Regulatory 50
Jun 26, 2017: Sunesis Pharmaceuticals added to Russell Microcap Index 50
Product News 51
12/05/2017: Sunesis Pharmaceuticals to Provide Program Update for Non-Covalent BTK Inhibitor SNS-062 at Analyst & Investor Event during ASH 2017 51
07/18/2017: Sunesis Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062 in Adults with Chronic Lymphocytic Leukemia and other B-Cell Malignancies 52
Product Approvals 53
May 01, 2017: Sunesis Pharmaceuticals Announces Withdrawal of European Marketing Authorization Application (MAA) for Vosaroxin as a Treatment for Relapsed/Refractory AML 53
Mar 22, 2017: Sunesis Pharmaceuticals Announces Submission of Responses to the EMA Day 180 List of Outstanding Issues for Marketing Authorization Application for Vosaroxin 54
Jan 23, 2017: Sunesis Pharmaceuticals Provides Update on SNS-062 55
Jan 23, 2017: Sunesis Pharmaceuticals Provides Update on Vosaroxin 56
Clinical Trials 57
Apr 03, 2017: Sunesis Pharmaceuticals Announces Presentation of The Ohio State University-Sponsored Preclinical Study of BTK Inhibitor SNS-062 at AACR Annual Meeting 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58

List of Tables
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sunesis Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sunesis Pharma Enters Into Licensing Agreement With Biogen Idec 11
Sunesis Pharma Enters Into Licensing Agreement With Millennium Pharma 13
Sunesis Pharma to Raise up to USD15.5 Million in Private Placement of Shares 14
Sunesis Pharmaceuticals Raises USD20 Million in Public Offering of Shares 16
Sunesis Pharma Raises USD28 Million in Public Offering of Shares 18
Sunesis Pharma Raises USD17 Million in Public offering of Preferred Shares 20
Sunesis Pharma Raises USD9 Million in Public Offering of Shares 21
Sunesis Pharma Raises USD17 Million in Public Offering of Shares 23
Sunesis Pharma Prices Public offering of Shares for USD8 Million 25
Sunesis Pharma Completes Public Offering Of Common Stock And Warrants For US$43 Million 26
Royalty Pharma Completes Acquisition Of Royalty Agreement For Vosaroxin From Sunesis Pharma For US$25 Million 27
Sunesis Pharmaceuticals Inc, Key Competitors 29
Sunesis Pharmaceuticals Inc, Key Employees 30
Sunesis Pharmaceuticals Inc, Subsidiaries 31

List of Figures
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Sunesis Pharmaceuticals Inc (SNSS):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • DB HiTek Co Ltd (000990):企業の財務・戦略的SWOT分析
    DB HiTek Co Ltd (000990) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Taconic Biosciences Inc:医療機器:M&Aディール及び事業提携情報
    Summary Taconic Biosciences Inc (Taconic), formerly Taconic Farms Inc is a research model provider that offers animal health models and laboratory services. The company’s products include taconic transgenic mouse models, emerging models, cryopreserved models, traditional models, diet induced obese, …
  • Colorado State University-製薬・医療分野:企業M&A・提携分析
    Summary Colorado State University (CSU) is a public research university that offers various academic programs. It provides graduate degree programs, undergraduate degree programs, research programs, summer programs and honor programs. Its schools and programs include graduate school, international p …
  • Ryder System, Inc.:企業の戦略・SWOT・財務情報
    Ryder System, Inc. - Strategy, SWOT and Corporate Finance Report Summary Ryder System, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Cathay Life Insurance Co Ltd:企業の戦略・SWOT・財務情報
    Cathay Life Insurance Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Cathay Life Insurance Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • The National Commercial Bank
    The National Commercial Bank - Strategy, SWOT and Corporate Finance Report Summary The National Commercial Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Anthem, Inc.:企業のM&A・事業提携・投資動向
    Anthem, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Anthem, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Stanwell Corporation Ltd:発電所・企業SWOT分析
    Stanwell Corporation Ltd - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key empl …
  • Personal Genome Diagnostics Inc:医療機器:M&Aディール及び事業提携情報
    Summary Personal Genome Diagnostics Inc (PGD) is a genomic solution provider. The company develops next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes. It provides a portfolio of regulated tissue-based and liquid biopsy genomic products for laborat …
  • Sorrento Therapeutics, Inc.:企業のM&A・事業提携・投資動向
    Sorrento Therapeutics, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sorrento Therapeutics, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Fresh Del Monte Produce Inc.:企業の戦略・SWOT・財務情報
    Fresh Del Monte Produce Inc. - Strategy, SWOT and Corporate Finance Report Summary Fresh Del Monte Produce Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Caladrius Biosciences Inc (CLBS):製薬・医療:M&Aディール及び事業提携情報
    Summary Caladrius Biosciences Inc (Caladrius), formerly NeoStem Inc, is a cell therapy service provider. The company offers multiple technology platforms targeting cardiovascular indications and autoimmune diseases. It offers products to target type one diabetes mellitus, used to treat imbalance in …
  • GHD Pty Ltd:企業の戦略・SWOT・財務分析
    GHD Pty Ltd - Strategy, SWOT and Corporate Finance Report Summary GHD Pty Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Pacific Hydro Pty Ltd:電力:M&Aディール及び事業提携情報
    Summary Pacific Hydro Pty Ltd (Pacific Hydro), a subsidiary of State Power Investment Corporation is an energy solutions provider that undertakes the development and operations of the renewable power projects. The company offers wind, hydro, solar and geothermal power projects at varying stages of d …
  • Vallourec SA:企業のM&A・事業提携・投資動向
    Vallourec SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Vallourec SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Peabody Energy Corporation:企業のM&A・事業提携・投資動向
    Peabody Energy Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Peabody Energy Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • HealthCare Global Enterprises Ltd (HCG)-製薬・医療分野:企業M&A・提携分析
    Summary HealthCare Global Enterprises Ltd (HCG), formerly Curie Centre of Oncology Private Ltd is a healthcare service provider that offers medical care and treatment services. The company offers services such as clinical laboratory services, diagnosis services, medical oncology services, radiation …
  • Immatics Biotechnologies GmbH-製薬・医療分野:企業M&A・提携分析
    Summary Immatics Biotechnologies GmbH (Immatics) is a clinical stage biopharmaceutical company that develops drugs for the treatment of cancer. It develops peptide based active immunotherapy drug candidates based on it novel technology, XPRESIDENT discovery platform. The company has active programs …
  • Tecpetrol SA:石油・ガス:M&Aディール及び事業提携情報
    Summary Tecpetrol SA (Tecpetrol), a subsidiary of Techint Group, is an oil and gas exploration and production company. The company acquires, explores, produces, transports and distributes oil and gas. It operates fields and blocks in Argentina, Venezuela, Bolivia, Ecuador, Mexico, Peru and Colombia. …
  • PhoenixBio Co Ltd (6190):企業の財務・戦略的SWOT分析
    Summary PhoenixBio Co Ltd (PhoenixBio) is a life science company that offers medical therapy solutions. The company offers contract study services including dosing of test-compounds, sampling, in-life phase trials, chemical analysis, measurement of human albumin levels, and metabolic enzymes and blo …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆